963P Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315

W.E.E Eberhardt,B Passlick,M Stuschke,A Groeschel,P Christopoulos,M Reck,P Ludwig,A Hipper,M Chiabudini,L Spring,M Jänicke,A Andres-Pons,D.C Christoph,C Bernhardt,M Reiser,M Sebastian,F Griesinger,M Thomas

doi:10.1016/j.annonc.2022.07.1089

963P Clinical research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-world evidence of NSCLC patients treated with radiochemotherapy in Germany – AIO-TRK-0315

W.E.E Eberhardt, B Passlick + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1089

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: German Center for Lung Research, Pius Hospital Oldenburg

#Routine Care In Germany #Lung Cancer In Germany + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

CRISP is a non-interventional, prospective, multi-center clinical research platform to understand the treatment reality of patients (pts) with lung cancer in Germany. Locally advanced non-small cell lung cancer (NSCLC) is a heterogenous group with several treatment approaches possible. Here we present data of pts treated with radiochemotherapy (RTCTx) in routine care in Germany.

Full Text